ANONDITA2025-10-012026-03-31ANONDITA2026-03-31ANONDITA2025-03-31ANONDITA2025-04-012026-03-31ANONDITA2025-10-012026-03-31in-capmkt:OtherExpenses1MemberANONDITA2025-04-012026-03-31in-capmkt:OtherExpenses1MemberANONDITA2026-03-31OtherCurrentLiabilitiesDomain1ANONDITA2026-03-31OtherNoncurrentAssetsDomain1ANONDITA2026-03-31OtherCurrentAssetsDomain1ANONDITA2025-10-012026-03-31RelatedPartyTransactionDomain1ANONDITA2025-09-30RelatedPartyTransactionDomain1ANONDITA2026-03-31RelatedPartyTransactionDomain1ANONDITA2025-10-012026-03-31RelatedPartyTransactionDomain2ANONDITA2025-09-30RelatedPartyTransactionDomain2ANONDITA2026-03-31RelatedPartyTransactionDomain2ANONDITA2025-10-012026-03-31RelatedPartyTransactionDomain3ANONDITA2025-09-30RelatedPartyTransactionDomain3ANONDITA2026-03-31RelatedPartyTransactionDomain3ANONDITA2025-10-012026-03-31RelatedPartyTransactionDomain4ANONDITA2025-09-30RelatedPartyTransactionDomain4ANONDITA2026-03-31RelatedPartyTransactionDomain4ANONDITA2025-10-012026-03-31RelatedPartyTransactionDomain5ANONDITA2025-09-30RelatedPartyTransactionDomain5ANONDITA2026-03-31RelatedPartyTransactionDomain5ANONDITA2025-10-012026-03-31RelatedPartyTransactionDomain6ANONDITA2025-09-30RelatedPartyTransactionDomain6ANONDITA2026-03-31RelatedPartyTransactionDomain6ANONDITA2025-10-012026-03-31RelatedPartyTransactionDomain7ANONDITA2025-09-30RelatedPartyTransactionDomain7ANONDITA2026-03-31RelatedPartyTransactionDomain7ANONDITA2025-10-012026-03-31RelatedPartyTransactionDomain8ANONDITA2025-09-30RelatedPartyTransactionDomain8ANONDITA2026-03-31RelatedPartyTransactionDomain8ANONDITA2025-10-012026-03-31RelatedPartyTransactionDomain9ANONDITA2025-09-30RelatedPartyTransactionDomain9ANONDITA2026-03-31RelatedPartyTransactionDomain9ANONDITA2025-10-012026-03-31RelatedPartyTransactionDomain10ANONDITA2025-09-30RelatedPartyTransactionDomain10ANONDITA2026-03-31RelatedPartyTransactionDomain10ANONDITA2025-10-012026-03-31RelatedPartyTransactionDomain11ANONDITA2025-09-30RelatedPartyTransactionDomain11ANONDITA2026-03-31RelatedPartyTransactionDomain11ANONDITA2025-10-012026-03-31RelatedPartyTransactionDomain12ANONDITA2025-09-30RelatedPartyTransactionDomain12ANONDITA2026-03-31RelatedPartyTransactionDomain12ANONDITA2025-10-012026-03-31RelatedPartyTransactionDomain13ANONDITA2025-09-30RelatedPartyTransactionDomain13ANONDITA2026-03-31RelatedPartyTransactionDomain13ANONDITA2025-10-012026-03-31AuditorDomain1ANONDITA2026-03-31Statement1ANONDITA2025-10-012026-03-31Statement1ANONDITA2026-03-31StatementDynamic1I1Statement1ANONDITA2026-03-31StatementDynamic1I2Statement1ANONDITA2026-03-31StatementDynamic1I3Statement1iso4217:INRxbrli:pureiso4217:INRxbrli:shares000000ANONDITANOTLISTEDINE0VTV01012ANONDITA MEDICARE LIMITEDSMEEquity2025-04-012026-03-312026-05-222026-05-16INRLakhsHalf YearlyYearlySingle segmentManufacture of Condoms2026-05-2213:00:002026-05-2220:30:00trueCash Flow IndirectDeclaration of unmodified opiniontruetrueNANAfalsetrue2025-08-01https://anonditamedicare.com/AMLPolicy.phptrue1falseThe Company has not defaulted in payment of Loan and Debt securities or its interest2025-10-012026-03-31AuditedStandalone640456000100350006504910002867910000-156250003919300016695000670900010486200043862500021186600002118660000211866000413750001694700058322000153544000000153544000153544000180866000108.498.492025-04-012026-03-31AuditedStandalone11169620001759100011345530005221130000-34319000662990003482700010712000169784000769416000365137000036513700003651370007843900018497000969360002682010000002682010002682010001808660001094943800016.6516.65Other Expenses104862000Other Expenses16978400018086600094943800011303040000235962000193520001780000257094000967800001412300065264000793870001938500046362000241914000162931200039079800004149500008057480003515800022079000160008630010000134914000379880000218600093224000110975000451320007663110001629312000Other Current Liabilities19385000Other Non-current Asset16000Other Current Asset4513200033762000107120000000008000044482000-45286000-213837000-4130800044129000-52143000-31108000-339553000-29507100070066000000321790000378870000037887000000000000627983000000000010650000127010000-61421700000-6142170006949850000011688600000348270000-1088600006681840000066818400091854000091854000355600095410000Anondita Medicare Limited******Anondita Healthcare Products Private Limited******ENTITY UNDER COMMON CONTROL PROMOTERAny other transactionRenting on Property9912000NA991200015860000Anondita Medicare Limited******Anondita Healthcare Products Private Limited******ENTITY UNDER COMMON CONTROL PROMOTERAny other transactionSecurity Deposit on Rental PropertyNA019500001950000Anondita Medicare Limited******Anondita Healthcare & Rubber Products India Limited******SUBSIDIARY COMPANYSale of goods or services60053000NA600530003240600033247000Anondita Medicare Limited******Anondita Healthcare & Rubber Products India Limited******SUBSIDIARY COMPANYLoan44250000NA4425000015790900057189000Loan0.12 yearsUnsecuredfor ordinary course of businessAnondita Medicare Limited******Anondita Healthcare & Rubber Products India Limited******SUBSIDIARY COMPANYLoan151888000NA15188800000Loan0.12 yearsUnsecuredfor ordinary course of businessAnondita Medicare Limited******Anondita Healthcare & Rubber Products India Limited******SUBSIDIARY COMPANYInterest received6919000NA691900000Anondita Medicare Limited******Anondita Healthcare (PARTNERSHIP FIRM)******ENTITY UNDER COMMON CONTROL PROMOTERAny other transactionCar Rental Services8850000NA885000014500000Anondita Medicare Limited******Anondita Latex Private Limited******ENTITY UNDER COMMON CONTROL PROMOTERAdvanceNA031660003166000Anondita Medicare Limited******Anondita Latex Private Limited******ENTITY UNDER COMMON CONTROL PROMOTERSale of goods or servicesNA0325000325000Anondita Medicare Limited******Anondita Healthcare Products Private Limited******ENTITY UNDER COMMON CONTROL PROMOTERAny other transactionCorporate Guarantee Received37400000NA37400000037306000Anondita Medicare Limited******Anupam Ghosh******ENTITY UNDER COMMON CONTROL PROMOTERAny other transactionPersonal Guarantee Received40000000NA40000000040000000Anondita Medicare Limited******Anondita Healthcare Products Private Limited******ENTITY UNDER COMMON CONTROL PROMOTERAny other transactionLoan Guarantee Fees441000NA44100000Anondita Medicare Limited******Anondita Healthcare******ENTITY UNDER COMMON CONTROL PROMOTERAny other transactionSecurity Deposit for Car Rental ServiceNA025000002500000359713000AuditedtrueJain Chopra and Companytrue2029-03-31Public Issues2025-08-286949000002026-03-31trueInfomerics Valuation and Rating Limitedtruetrue2026-02-12As disclosed in the Prospectus dated 28 August 2025, the original objects of the issue were Capital Expenditure (CAPEX), Funding Working Capital Requirements, General Corporate Purposes (GCP) and Unidentified Acquisition. During the quarter ended September 30 2025 andDecember31 2025 and March 31, 2026, certain modifications and reallocations were made in the utilization of IPO proceeds. Subsequently, the shareholders approved and ratified the revised utilization and reallocation of funds through a Special Resolution passed at the Extra-Ordinary General Meeting of the Members held on 12 February 2026. Accordingly: • An amount of ₹278.41 lakhs was reallocated from General Corporate Purposes to Funding Working Capital Requirements, resulting in the revised allocation for working capital requirements increasing from ₹3500 Lakhs to ₹3778.41Lakhs. • The allocation towards General Corporate Purposes and Unidentified Acquisitionwas revised from ₹2015.87 Lakhs to ₹1737.46Lakhs and shall now be utilized only towards General Corporate Purposes within the revised regulatory limits. No unidentified acquisition shall be undertaken using the IPO proceeds. • • The Company has also revised the deployment timeline of funds under General Corporate Purposes. The entire balance amount was originally expected to be utilized within FY 2025–26; however, the remaining balance of Rs. 123.25 Lakhs shall now be utilized during FY 2026–27. • Further, the utilization towards working capital requirements increased due to expansion in the scale of operations and higher working capital needs. The original estimates were based on a projected turnover of ₹10,000 Lakhs for FY 2025–26, which was revised to approximately ₹14,500 Lakhs. • There is no material variation in the Capital Expenditure object except changes and/or additions to vendors, as disclosed in the Prospectus. Anupam GhoshManaging DirectorNoida2026-05-22CapexNo variation in object of the issue except changes and/or additions to vendors, as disclosed in the Prospectus600000000262100000Funding Working Capital RequirementsDue to revision in GCP limits (from 35% to 25%) under the revised SEBI guidelines, an amount of Allocation of Rs. 278.41 Lacs out of Object 3 (i.e., General Corporate Purposes) towards funding the Company’s working capital requirements, including working capital loans and Cash Credit (CC) limits and with this reallocation, the revised total allocation for working capital now stands at Rs. 3,778.41 Lacs. Furthermore, utilization under this object has exceeded the originally estimated utilization during financial year 2025-26 and 2026-27 due to the Company’s expanded scale of operations and higher working capital requirements and the working capital estimates were initially based on a projected turnover of ₹100 crore for FY 2025–26, which has now been revised to approximately ₹145 crore. 3500000003778410003575550000General Corporate Purpose (GCP) 1. for Unidentified Acquisition 2. For GCP (Capped at 25% of gross issue size) Due to revision in GCP limits (from 35% to 25%) under the revised SEBI guidelines, the funds allocated for Object 3 (Unidentified Acquisition and General Corporate Purposes) will to be utilized for GCP only, now restricted to 25% of the total IPO proceeds. Any amount excess of GCP Limit will be transferred towards meeting the Company’s working capital requirements. No unidentified acquisition will be undertaken using the IPO proceeds. Furthermore, the allocation of Rs. 278.41 Lacs from Object 3 to Object 2 for funding the Company’s working capital requirements, including working capital loans and Cash Credit Limit. With this reallocation, the revised total allocation for General Corporate Purposes stands at Rs. 1,737.46 Lacs. Further, while the utilization of these funds was initially projected over FY 2025–26 and FY 2026–27, it was subsequently expected that the entire allocation would be deployed within FY 2025–26. However, the balance amount shall now be utilized during the current financial year 2026–27. 2015870001737460001614210000